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Abstract
Background: Protein kinase inhibitors (PKIs) are currently tested in clinical studies (phase I-III) as an alternative
strategy against (recurrent) ovarian cancer. Besides their anti-tumour efficacy, several PKIs have also shown
radiosensitizing effects when combined with external beam radiation. Based on these results we asked if the
addition of PKIs offers a therapeutic opportunity to improve radioimmunotherapy (RIT) against ovarian cancer. Five
PKIs (alisertib, MK1775, MK2206, saracatinib, temsirolimus) were chosen for cytotoxicity screenings based on their
current clinical trials in the treatment of ovarian cancer and their influence on cell cycle regulation and DNA
damage repair pathways. We combined selected PKIs with 177Lu-labelled anti-L1CAM monoclonal antibody chCE7
for our investigations.
Methods: PKIs cytotoxicity was determined via cell colony-forming assays. Biomarker of DNA double-strand breaks
(DSBs, γH2A.X) was analysed by western blot and fluorescence microscopy. Flow cytometric measurements were
performed to evaluate levels of apoptosis based on mono- or combination treatments. The best combination was
used for in vivo combination therapy studies in nude mice with SKOV3ip and IGROV1 human ovarian cancer
xenografts. Bonferroni correction was used to determine statistical significance for multiple comparisons.
Results: The highest cytotoxicity against both cell lines was observed for MK1775 and alisertib. Combinations
including 177Lu-labelled mAb chCE7 and MK1775 decreased 177Lu-DOTA-chCE7 IC60-values 14-fold, compared to 6-fold,
when the radioimmunoconjugate was combined with alisertib. The most effective PKI MK1775 was further evaluated and
demonstrated synergistic effects in combination with 177Lu-DOTA-chCE7 against IGROV1 cells. Significantly higher
amounts of DSBs were detected in IGROV1 cells after combination (91%) compared to either treatment alone (MK1775:
52%; radioimmunoconjugate: 72%; p < 0.0125). Early-apoptosis was significantly enhanced in IGROV1 cells correlating with
induced DSBs (177Lu-DOTA-chCE7: 8%, MK1775: 28%, 177Lu-DOTA-chCE7 +MK1775: 40%, p < 0.0125).
Immunohistochemistry analysis of γH2A.X expression levels after therapy in SKOV3ip xenografts revealed a high sensitivity
of the tumour cells to MK1775 and a high radioresistance. A prominent effect of tumour growth inhibition of the RIT and
of the combination therapy was observed in vivo in a late stage IGROV1 xenograft model.
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Conclusions: Our results warrant further evaluation of combination of MK1775 and radioimmunotherapy.
Keywords: Protein kinase inhibitor, MK1775 (AZD1775), Ovarian carcinoma, L1CAM, mAb chCE7, 177Lu-
radioimmunotherapy, Combination therapy
Background
Today, epithelial ovarian cancer (OC) represents the
most severe gynaecological cancer in women. Approxi-
mately 75% of the affected patients are being diagnosed
with advanced-stage III or IV, since diagnostic markers
and clinical symptoms during early stages are mostly ab-
sent [1]. Cytoreductive surgery and paclitaxel-platinum
chemotherapy represent the most efficient therapy op-
tions for advanced OC. Despite good response rates to-
wards chemotherapies (50–80%), the major issue stays
the rather high relapse rate in patients within 2 years in-
cluding development of taxane or platinum resistant tu-
mours [2, 3].
Modern chemotherapeutic agents like etoposide,
gemcitabine, topotecan or pegylated liposomal doxo-
rubicin are frequently used against recurrent ovarian
cancers, but unfortunately, with very limited response
rates between 15 and 30% [4–7].
Given the high relapse rate of recurrent
platinum-resistant OC, overall survival is still limited
(approx. 40%) [8]. Alternative screening and therapy strat-
egies are urgently needed. New targeted therapies have
been investigated during the last couple of years with the
goal to increase overall survival and reduce side-effects.
Therefore, various monoclonal antibodies (mAbs) have
been studied as a targeted treatment alternative [9]. Unfor-
tunately, mAb-based mono- or combination therapies
showed only limited clinical efficacies against advanced OC
despite promising pre-clinical results [10–13]. Many re-
search groups focus on alternative therapeutic strategies in-
cluding several protein kinase inhibitors (PKIs) targeting
different signalling pathways or the DNA repair machinery
of cancer cells. Besides their efficacy against (recurrent)
OC, several PKIs also demonstrated radiosensitizing effects
when combined with ionizing radiation (external beam ra-
diation, EBRT) [14–16].
In previous studies we demonstrated the efficacy of
anti-L1CAM radionuclide-labelled mAb chCE7
(177Lu,161Tb, 67Cu) as monotreatment or when com-
bined with the chemotherapeutic paclitaxel (PTX)
against disseminated OC [17–20]. Based on these
findings we explored a new approach investigating the
potential synergy between PKIs and anti-L1CAM
radioimmunotherapy (RIT) against OC. In this con-
text is worth mentioning that high expression of
L1CAM in OC is associated with the rapid growth of
aggressive tumours and a poor prognosis for the
patients [21]. L1CAM “is a major driver for tumour
cell invasion and motility” [22].
Five PKIs were chosen for initial cytotoxicity screen-
ings based on their current clinical studies (OC clinical
trials I-II) and their potential radiosensitizing character-
istics. Briefly, PKIs candidates were chosen as follows:
Alisertib, an Aurora kinase A PKI, showed modest re-
sults in a clinical phase II trial against platinum-resistant
or refractory OC [23]. Additionally, a phase I trial is on-
going for the therapy of recurrent OC in combination
with the chemotherapeutic PTX (clinical trial identifier:
NCT01091428). Alisertib has shown to sensitize glio-
blastoma cells against radiation in vitro [14].
MK1775 also known as AZD1775 is an ATP-competitive
inhibitor of Wee1 tyrosine kinase. Wee1 is one of two ki-
nases (Wee1 and Mik1) that catalyse inhibitory phosphoryl-
ation on the CDC2-cyclin B complex [24, 25]. Inhibition of
Wee1 abrogates the G2/M arrest and leads to compelled
progression to mitosis despite damaged DNA resulting in
mitotic catastrophe [26]. MK1775 is under investigation in
different clinical trials (Phase II) in combination with gem-
citabine, carboplatin or paclitaxel against OC (clinical trial
identifier: NCT02101775 and NCT02272790) and has pre-
viously shown radiosensitizing characteristics in vivo when
combined with ionizing radiation for the treatment of in-
trinsic potine gliomas [27].
Temsirolismus is a mTOR inhibitor which has shown
modest, but not sufficient anti-tumour activity in a re-
cent phase II clinical trial as a monotherapy against per-
sistent/recurrent OC [28, 29]. A clinical phase II study
where temsirolimus was combined with bevacizumab
has been completed but no study results have been pub-
lished yet (clinical trial identifier: NCT01010126). The
radiosensitizing abilities of temsirolismus were shown in
vivo in a glioblastoma model [30].
Saracatinib is an inhibitor of Src tyrosine kinase and
was investigated in a phase II trial assessing its use in
combination with PTX and carboplatin in advanced OC
(clinical trial identifier: NCT00610714). However, results
remain to be published. Saracatinib revealed sensitizing
effects towards ionizing radiation in a lung cancer in
vitro model [16].
MK2206 is a highly selective inhibitor of Akt kinase
and was tested in a phase II clinical trial against
platinum-resistant OC (clinical trial identifier:
NCT01283035) [31]. The study has been recently com-
pleted. In addition it was demonstrated in vitro, that
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MK2206 can sensitize triple negative breast cancer cells
towards EBRT [32].
After initial in vitro screenings, we further investigated
combinations including PKI MK1775 and the 177Lu-la-
belled mAb chCE7 in vivo. Two OC cell lines (IGROV1,
p53wt, SKOV3ip, p53del) were used in our studies.
Methods
Cell lines, culture conditions and antibody formats
L1CAM positive SKOV3ip cells were kindly provided by
P. Altevogt (German Cancer Research Center, Heidel-
berg, Germany). Cells were established from ascitic fluid
of a nu/nu mouse that was previously injected with
SKOV3 cells [33]. SKOV3ip cells were maintained in
DMEM medium at 37 °C. IGROV1 cells were a kind gift
by Dr. Cristina Müller (Center for Radiopharmaceutical
Sciences, Paul Scherrer Institute) and were maintained
in RPMI 1640 medium at 37 °C. Both cell media were
supplemented with 10% fetal calf serum (FCS), 2 mM
glutamine, 100 units/ml penicillin, 100 μg/ml strepto-
mycin and 0.25 μg/ml fungizone (BioConcept, Allschwil,
Switzerland). The two cell lines were cultivated in a hu-
midified atmosphere containing 5% CO2. Cell lines were
authenticated by STR profiling (Department of Molecu-
lar Medicine, Aarhus University Hospital, Denmark;
DSMZ Authentication Service, Braunschweig, Germany)
and were mycoplasma free (Mycoplasma test kit, Appli-
Chem GmbH, Darmstadt, Germany). L1CAM expres-
sion in both cell lines was confirmed by flow cytometry
(Additional file 1: Figure S1). The cell lines did not re-
quire ethics approval.
Chimeric monoclonal antibody mAb chCE7 (human κ
light chain and human γ1 heavy chain) is an
IgG1-subtype. MAb chCE7 was produced in HEK293
cells and subsequently purified from cell culture super-
natant as previously described by Grünberg et al. [34].
Ligand substitution and 177Lu antibody radiolabelling
For ligand substitution, molar excess of p-SCN-Bn-DOTA
(Macrocyclics, Dallas, TX, USA) was individually adopted
to vary DOTA-to-mAb ratios for in vitro and in vivo ex-
periments, respectively as described elsewhere [20].
Briefly, p-SCN-Bn-DOTA was mixed with mAb chCE7 in
0.1 mol/L sodium phosphate buffer (pH 7.2). The pH was
adjusted to pH 9–10 using a saturated Na3PO4 solution
and was incubated over night at 30 °C with gentle shaking.
Using a NAP-5 column (GE Healthcare, Glattbrugg,
Switzerland) excess ligands were removed and buffer was
exchanged into 0.25 M CH3COONH4 (pH 5.5). Immuno-
conjugates were concentrated to 5 mg/ml and stored at −
80 °C. The number of chelators coupled to the mAb was
determined by mass spectroscopy [17]. For radiolabelling,
the radionuclide 177Lu (ITG, Garching, Germany) was
used 1 to 3 days post-specified calibration date. In brief,
100–450 MBq of 177Lu was added to 150 μg immunocon-
jugate and incubated in 0.25 M CH3COONH4 buffer
(pH 5.5) at 37 °C for 1 h. After radiolabelling, EDTA was
added to the reaction mixture (5 min) to a final concentra-
tion of 5 mM to complex free 177Lu. Radiolabelled anti-
bodies were purified via FPLC size exclusion
chromatography on a Superose 12 column (GE Health-
care, Glattbrugg, Switzerland) using phosphate-buffered
saline (PBS) as eluent with a flow rate of 0.5 ml/min.
Radioimmunoconjugates (RICs) eluted with a retention
time of 21 min [19]. The immunoreactive fraction [35] of
labelled antibody conjugates ranged from 60 to 83%.
In vitro cytotoxicity assays
In order to investigate the sensitivity of SKOV3ip and
IGROV1 cells towards selected PKIs (alisertib, MK1775,
MK2206, saracatinib, temsirolimus; all from Selleckchem,
LuBioScience, Luzern, Switzerland) were solved in DMSO
and the accordant half-maximal inhibitory concentration
(IC50) was determined via adapted colony-forming assays
[36]. OC cells were seeded into 6-well plates with a dens-
ity of 250 cells/well and incubated over night at 37 °C.
After adhesion cells were washed with PBS and incubated
with the relevant PKI with concentrations ranging from
0.1 to 1000 nM for 48 h at 37 °C. Cells were washed with
PBS and covered with regular supplemented cell culture
medium as previously described. Eleven to fourteen days
post plating, colonies were washed with PBS, fixed and
stained with crystal violet staining solution containing
0.05% crystal violet, 1% formaldehyde and 1% MeOH for
15 min at room temperature (RT). Colonies were washed
twice with PBS and manually counted ([36], adapted). Col-
onies containing more than 100 cells were considered for
counting.
In combination experiments, cells were incubated with
the half of the half-maximal inhibitory concentration
(half IC50) of PKIs for 48 h at 37 °C. 1 ml
177Lu-DO-
TA-chCE7 solution was added either before, simultan-
eously, or post PKI application in concentrations
ranging from 0.05 to 5 MBq/ml for 8 h at 37 °C. The in-
cubation medium was removed at the indicated time
points and cells were washed with PBS and incubated
with regular supplemented cell culture medium. Again,
11–14 days post plating, colonies were washed with PBS,
fixed, stained and counted as described.
Western blot analysis
Cells were exposed to accordant mono- or combination
treatments including IC50 of MK1775 (300 nM) for
48 h and/or 5 MBq/ml 177Lu-DOTA-chCE7 (5 ml) for
8 h. Cell lysates were subject to SDS-polyacrylamide
gelelectrophoresis. Proteins were transferred onto poly-
vinylidene difluoride (PVDF) membranes (Immobilon,
Merck, Schaffhausen, Switzerland) via a semi-dry
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blotting device (Bio-Rad Laboratories AG, Reinach,
Switzerland) and incubated with primary anti-CDC2
(1/1000) -pCDC2 (Tyr-15; 1/1000) or -GADPH (1/
1000) antibodies (Cell Signaling Technology, Biocon-
cept, Allschwill, Switzerland). Detection of proteins was
performed with secondary anti-mouse IgG HRP-linked
antibody (1/2000, 30 min, RT; Cell Signaling Technol-
ogy, Bioconcept, Allschwill, Switzerland) and ECL
chemiluminescence kit (Perbio Science Switzerland
S.A., Lausanne, Switzerland). All antibody dilutions
were made in TBST/2% BSA and were incubated over
night at 4 °C.
For the detection of histone phosphorylation γH2A.X
(Ser-139) Abcam’s histone extraction protocol was used.
Briefly, cells were detached from plates and washed
twice with ice-cold PBS containing 5 nM sodium butyr-
ate to retain levels of histone acetylation. Washed cells
were resuspended and incubated for 10 min in triton ex-
traction buffer (TEB) containing 0.5% triton-X 100 (v/v),
2 mM phenylmethylsulfonylfluoride (PMSF) and 0.02%
(w/v) NaN3. Suspended cells were centrifuged at
2000 rpm for 10 min at 4 °C, washed in half the volume
of TEB buffer, centrifuged again (2000 rpm/10 min/4 °C)
and incubated overnight (4 °C) in 0.2 N HCl (75 μL) to
extract histones. The next day, cells were again centri-
fuged as before and the protein concentration of the
supernatant determined via advanced protein assay re-
agent (Cytoskeleton, Inc., Denver, USA). Aliquots were
stored at − 20 °C and subjected to western blot analysis
as previously described.
Fluorescence microscopy
Cells were seeded in an 8-well chamber system (Nunc
Lab-Tek II Chamberslides, Thermo Fisher Scientific, Rein-
ach, Switzerland) with 15.000 cells per chamber and incu-
bated over night at 37 °C. After adhesion cells were
treated with MK1775 (100 nM, 300 μl) for 48 h and/or
2.5 MBq/ml 177Lu-DOTA-chCE7 (300 μl) for 4 h. Cells
were washed three times with PBS and incubated for
15 min with PBS/4% formaldehyde for fixation. Subse-
quently, cells were washed and incubated with 0.2%
permeabilization buffer containing 0.03 M NaCl, 0.3 mM
KH2PO4, 0.5 mM Na2HPO4 and 3% triton-X 100 diluted
with PBS for 15 min at RT. Cells were blocked with PBS/
1% BSA, 0.3% Tween-20 for 45 min and incubated over
night with the primary anti-γH2A.X antibody (1/400, 4 °C,
Cell Signaling Technology, Bioconcept, Allschwill,
Switzerland) diluted in blocking buffer. Cells were incu-
bated with a reaction mixture containing secondary fluor-
escein isothiocyanate (FITC)-conjugated antibody (1/300,
Abcam, Cambridge, UK) and phalloidin (1/200, Cell Sig-
naling Technology, Bioconcept, Allschwill, Switzerland)
for 30 min at RT, washed three times and stored at 4 °C in
the dark. Samples were imaged with a Leica SP5 confocal
microscope (Leica Microsystems, Switzerland) using a
50 × 0.5NA dry objective. Fields were chosen at random
locations. γH2A.X foci were calculated as a percentage of
the total cells counted in each field.
Apoptosis analysis via flow cytometry
Cells were treated with 300 nM MK1775 for 48 h and/or
5 MBq/ml 177Lu-DOTA-chCE7 (5 ml) for 8 h, detached,
washed and subjected to apoptosis analysis via flow cy-
tometry using an annexinV-FITC/propidium iodide (PI)
double staining. Cells were incubated for 15 min with an
annexinV-FITC/PI reaction mixture containing 10 mM
Hepes/NaOH, pH 7.4; 140 mM NaCl; 5 mM CaCl2; as
well as 20 μl of annexinV-FITC labelling reagent (Roche
Diagnostics GmbH, Mannheim, Germany) and 20 μl PI
solution (Flucka, Buchs, Switzerland). Labelled cells were
transferred into a 96-well plate, analysed by flow cytom-
etry and results were evaluated with FlowJo software
(Tree Star, Ashland, OR, USA, version 10).
In vivo studies
All animal experiments were approved by the cantonal
committee on animal experiments and permitted by the
responsible cantonal authorities (permission number
75666, Kanton Aargau). The studies were conducted in
compliance with the Swiss laws on animal protection.
For tumour growth, groups of 4–6 female CD-1nu mice
(Charles River, Sulzfeld, Germany, 5 weeks old, with an
average weight of 22 g) were injected subcutaneously
(s.c.) with 5 × 106 IGROV1 cells (100 μl, in sterile PBS)
into the right flank. One week before the radioimmu-
notherapy started, 200 μg of murine IgG2a (#M7769,
Sigma-Aldrich, Buchs, Switzerland) was injected i.p. to
minimize unspecific binding to murine Fcɣ and FcRn re-
ceptors. Nineteen days post tumour cell inoculation
(mean tumour volume: 362 ± 150 mm3, mean body
weight: 24.8 ± 1.6 g) mice were treated with a) 6 MBq
(50% maximum tolerated activity (MTA) [20], 25 μg,
100 μl 177Lu-DOTA-chCE7, b) 6 MBq177Lu-DOTA-iso-
type control antibody (25 μg, 100 μl) or c) PBS into the
tail vein. In some treatment groups MK1775 (50 mg/kg,
CliniSciences, Nanterre, France) was given in DMSO in
0.5% methylcellulose (M0512; Sigma-Aldrich, Buchs,
Switzerland) in a 1:14 suspension [37] by oral gavage on
three consecutive days starting 48 h after RIT. The gav-
age needle was precoated with sucrose to reduce stress
for the mice [38].
For the in vivo assessment of DNA damage, female
CD-1nu mice (n = 3; Charles River, Sulzfeld, Germany)
were subcutaneously (s.c.) injected with 5 × 106 SKO-
V3ip cells and 14 days later treated with 2 MBq of intra-
venously (i.v.) administered 177Lu-DOTA-chCE7 alone
or in combination with 50 mg/kg MK1775 administered
p.o. 48 h after RICs. PKI doses were administered daily
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for 3 consecutive days. Accordantly, controls received
PBS. Six days post therapy start all animals were eutha-
nized. Subcutaneous xenografts were measured, removed
and fixed in 4% neutral-buffered formalin (Formafix, Hitt-
nau, Switzerland) for 48 h. After fixation tissues were
trimmed, dehydrated in graded alcohol and routinely par-
affin wax embedded. Consecutive sections (3–5 μm thick)
were prepared, mounted on glass slides and routinely
stained with haematoxylin and eosin (HE) or subjected to
immunohistochemical staining.
A rabbit polyclonal antibody against mouse phosphory-
lated γH2A.X histone antigen (antibody #2577, Cell Sig-
naling Technology, Bioconcept, Allschwill, Switzerland)
was used to detect endogenous levels of γH2A.X when
phosphorylated at serine 139. Briefly, sections were depar-
affinised in xylene rehydrated in decreasing concentra-
tions of ethanol and subjected to antigen retrieval using
10 mM Tris-EDTA buffer (pH 9.0) for 15 min at 98 °C.
This was followed by incubation for 15–18 h at 4 °C with
the primary antisera (1/50 dilution in Dako antibody dilu-
ent, Dako-Agilent Technologies, Denmark). A detection
kit containing the secondary antibody and diaminobenzi-
dinetetrahydrochloride (DAB) as chromogen was subse-
quently applied according to the manufacturer’s protocols
(Peroxidase/DAB+ Rabbit/Mouse Kit; DAKO-Agilent
Technologies, Denmark), followed by light counterstain
with hematoxylin.
An attempt was made to quantify the number of
γH2A.X positive tumour cells. Slides were scanned using
digital slide scanner NanoZoomer-XR C12000 (Hama-
matsu, Japan) and images (10 images per sample, 40×)
were taken using NDP.view2 viewing software (Hama-
matsu). Fields were selected just beneath the capsule of
the xenografts, avoiding areas exhibiting liquefactive ne-
crosis. Immuno-stained cells for γH2A.X were calculated
as a percentage of the total cells counted in each field.
Statistical analysis
Statistical analysis of apoptosis, fluorescence microscopy,
and histological data was performed using student’s t-test
(two-tailed, unpaired) with Bonferroni-correction. Signifi-
cance was determined with p < 0.0125. In vitro data was
analysed via combination index calculations (CI = (CA,x/
Icx,A) + (CB,x/Icx,B)). Thereby, concentrations required to
produce a given effect are determined for drug A (Icx,A) and
drug B (Icx,B). CA,x and CB,x are the concentrations of A and
B contained in combination that provide the same effect.
Synergy is determined for CI < 1, additivity for CI = 1 and
antagonism for CI > 1 [39].
Results
Antibody radiolabelling and ligand substitution
In order to determine the DOTA-to-mAb (chCE7) ratio
a mass spectroscopic analysis was performed. Results
showed that an average of 7.6 chelators was coupled to
one intact antibody molecule for RICs used in in vitro
experiments. For RICs utilized in the in vivo study an
average of 2.7–3.1 chelators was coupled. Specific activ-
ity ranged from 2000 to 2850 MBq/mg for RICs with 7.6
chelators and 240–560 MBq/mg for RICs with 2.7–3.1
chelators. Lindmo method [35] was used to prove the
immunoreactive fraction of the radiolabelled mAbs (60–
83%).
Cytotoxicity of selected PKIs towards IGROV1 and
SKOV3ip cells
First we investigated the sensitivity of the IGROV1 and
SKOV3ip OC cell lines towards the selected PKIs. Re-
spective dose-response curves are shown in Fig. 1a-e
and resulting IC50-values are summarised in Table 1.
PKIs alisertib and MK1775 showed IC50-values in the
medium nanomolar range for both OC cell lines. Com-
parable sensitivities of SKOV3ip cells were observed to-
wards the PKIs temsirolimus and MK2206. In
comparison, IC50-values for temsirolimus and MK2206
against IGROV1 cells could only be estimated within in
the micromolar range, since highest applied PKI concen-
tration of 1 μM was not sufficient enough to reach IC50.
No cytotoxicity was detected for both cell lines based on
the treatment with PKI saracatinib (Fig. 1b).
MK1775 sensitizes IGROV1 cells towards treatment with
177Lu-DOTA chCE7 in vitro
PKIs saracatinib, MK2206 and temsirolimus showed
only limited cytotoxicities against both OC cell lines and
were therefore not considered for further investigations.
First in vitro combination experiments were performed
using the PKIs alisertib and MK1775 combined with
177Lu-DOTA-chCE7. Both PKIs demonstrated their abil-
ity to radiosensitize IGROV1 cells by lowering the in-
hibitory concentration of 177Lu-labelled mAb chCE7
necessary to reduce colony-forming ability to 60% of an
untreated control (IC60). However, MK1775 decreased
the IC60-value of
177Lu-DOTA-chCE7 15-fold compared
to a 6-fold decrease observed for combinations including
PKI alisertib (Additional file 1: Figure S2). In this experi-
ment the cells were incubated for only 4 h instead of 8 h
with 177Lu-labelled chCE7. The colony-forming ability
was reduced by a maximum of 60% in comparison to
the untreated cells even with the highest amount of
radioactivity.
Based on these findings MK1775 demonstrated the
most promising radiosensitizing effect and was therefore
further investigated. Following experiments included the
examination of different treatment sequences for com-
bined applications of MK1775 and 177Lu-DOTA-chCE7
in IGROV1 cells.
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The most prominent effects in IGROV1 were achieved
when MK1775 (half IC50) was added simultaneously or
post the radioimmunoconjugate (Fig. 2). IC50-value of
177Lu-DOTA-chCE7 was thereby lowered from 1.4 MBq/
ml to 0.8 MBq/ml (simultaneous application), or down to
0.5 MBq/ml (MK1775 post RIC). MK1775 pre-treated
cells showed no increased sensitivity towards the RIC but
rather an increased IC50-value of 3.9 MBq/ml compared
to 177Lu-DOTA-chCE7 alone. Combination index (CI)
calculations as previously described by Zhao et al. [39]
were used to determine synergy (Fig. 2, calculations are
shown in Additional file 1: Table S1). The additional
application of MK1775 (half IC50) post
177Lu-DO-
TA-chCE7 increased the cytotoxic effect of the RIC in a
synergistic manner (CI < 1). The IC50 value for radioresis-
tance towards 177Lu-DOTA-chCE7 was 4.7 MBq/ml for
SKOV3ip cells (data not shown).
The combination of MK1775 and RIC increases the
amount of induced DNA-double strand breaks (DSBs)
compared to monotreatments in IGROV1 cells
In order to elucidate the molecular mechanism behind
the observed radiosensitizing effect of the Wee1 kinase
inhibitor MK1775 on IGROV1 cells we investigated the
Fig. 1 IC50-values for a Alisertib, b Saracatinib, c MK1775, d Temsirolimus and e MK2206. IC50-values were determined by colony-forming assays.
IGROV1 and SKOV3ip cells were incubated for 48 h with accordant PKI concentrations ranging from 0.1–1000 nM
Table 1 IC50-values for PKIs against IGROV1 and SKOV3ip cells
Alisertib Saracatinib MK1775 Temsirolimus MK2206
IGROV1 50 ± 3 nM n.a. 306 ± 4 nM n.a. n.a.
SKOV3ip 158 ± 3 nM n.a. 133 ± 4 nM 120 ± 4 nM 131 ± 3 nM
Abbreviation: n.a. not available
Lindenblatt et al. BMC Cancer  (2018) 18:922 Page 6 of 14
phosphorylation status of cyclin-dependent-kinase 1
(alias CDC2), which is phosphorylated by protein kinase
(PK) Wee1. Additionally, we correlated the phosphoryl-
ation of CDC2 (pCDC2) with the amount of induced
DNA-DSBs by western blot analysis.
It seems, that in IGROV1 cells expression levels of
CDC2 were similar independent of a RIC and/or MK1775
application. Phosphorylation status of CDC2 (pCDC2)
looks equal for the control and 177Lu-DOTA-chCE7.
However, mono- or combined treatments containing
MK1775 appears to reduce the levels of pCDC2 compared
to controls or 177Lu-DOTA-chCE7 (Fig. 3).
Phosphorylation of histone H2A.X at Ser-139 (γH2A.X)
was detected as an indicator for presence of DNA-DSBs.
177Lu-DOTA-chCE7 treated cells showed slightly higher
amounts of γH2A.X compared to the control. The
addition of MK1775 increased markedly the levels of
γH2A.X compared to 177Lu-DOTA-chCE7 and the un-
treated cells. Combination of the RIC and PKI MK1775
showed the highest levels of γH2A.X, thus indicating the
largest amount of induced DNA-DSBs compared to either
treatment alone or the control (Fig. 3).
Fluorescence microscopy studies were conducted to
quantify γH2A.X levels. The number of induced γH2A.X
foci were counted and cells grouped depending on either
no observed γH2A.X foci (Fig. 4a), count of foci per cell
≤5 (Fig. 4b), count of foci per cell ≥6 (Fig. 4c), or
non-distinguishable γH2A.X foci (intensively positive,
Fig. 4d). All counts are summarized in Additional file 1:
Table S2. Figure 4e shows all γH2A.X positive cells
expressed in percent of total cell numbers counted.
Non-treated IGROV1 cells were positively tested for
γH2A.X foci (52 ± 19%), indicating that about half of
IGROV1 cells show a basal level of existing of
DNA-DSBs. After treatment with a low concentration of
MK1775 (100 nM) IGROV1 showed comparable amounts
of γH2A.X foci (55 ± 2%). In contrast, 177Lu-DO-
TA-chCE7 application resulted in an increased number of
72 ± 1%. Highest amounts of induced DNA-DSBs were
observed for the combination demonstrating 91 ± 4% of
IGROV1 cells being positive for γH2A.X foci. The total
number of positive cells thereby significantly increased
compared to either monotreatment (vs. MK1775: p <
0.0125; vs. 177Lu-DOTA-chCE7: p < 0.0125; Fig. 4e).
The number of cells showing ≤5 foci was similar for
cells treated with 177Lu-labelled mAb or combination
and amount of cells showing ≥6 foci was comparable all
in groups (Additional file 1: Table S2). Interestingly,
upon combination of both agents the number of inten-
sively positive cells raised from 2 ± 1% (177Lu-DO-
TA-chCE7) and 5 ± 3% (MK1775) to 15 ± 7%. Based on
these numbers, the significant increase in overall positive
cells for the combination is mostly due to the higher
amounts of intensively positive cells.
Fig. 2 Radiosensitivity of IGROV1 cells. The radiosensitivity was determined by colony-forming assays after combined treatments with 177Lu-
DOTA-chCE7 (range: from 0.01–5.0 MBq/ml, for 8 h) and MK1775 (applied simultaneously, 48 h post, or 48 h pre RIC with a concentration of
half IC50)
Fig. 3 Western blot analysis of CDC2, phosphorylated CDC2 and
phosphorylation of H2A.X in IGROV1 cell lysates. Cells were treated
with either 5 MBq/ml 177Lu-DOTA-chCE7 for 8 h or 300 nM MK1775
for 48 h. For combination, cells were simultaneously incubated with
both agents. After incubation (8 h) 177Lu-DOTA-chCE7 was removed
and MK1775 further incubated until 48 h were reached. All cell
lysates were taken directly post MK1775 treatment. Loading control:
GADPH (glyceraldehyde 3-phosphate dehydrogenase)
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Fig. 4 Fluorescence microscopy of γH2A.X. IGROV1 cells were incubated with 2.5 MBq 177Lu-DOTA-chCE7 for 4 h or with 100 nM MK1775 for
48 h. For combination, cells were simultaneously incubated with both agents. After 4 h incubation, 177Lu-DOTA-chCE7 was removed and MK1775
was further incubated until 48 h were reached. Cells were fixed and stained and γH2A.X foci were counted and cells grouped depending on (a)
no observed (b)≤ 5 (c)≥ 6 or (d) non-distinguishable γH2A.X foci (intensively positive). a-d shows examples of IGROV1 cells with accordant
numbers of γH2A.X foci. (e) summarizes all γH2A.X positive cells expressed in percent of total cell numbers counted
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The combination of MK1775 and RIC increase early-
apoptosis compared to monotreatments in IGROV1
To investigate if induced DNA-DSBs result in apoptosis/
necrosis, flow cytometry analysis was performed. Cells
were either untreated (Additional file 1: Figure S3A), or
incubated with MK1775 (Additional file 1: Figure S3B),
177Lu-DOTA-chCE7 (Additional file 1: Figure S3C), or
both (Additional file 1: Figure S3D). AnnexinV-FITC/PI
double staining was used to distinguish between early-
and late-apoptosis/necrosis.
IGROV1 cells treated with 177Lu-DOTA-chCE7 dem-
onstrated a doubling in early apoptotic cells compared
to controls (177Lu-DOTA-chCE7: 8 ± 2%; control: 4 ±
1%). The incubation with 300 nM (IC50) MK1775
showed elevated levels of 29 ± 10% of cells being early
apoptotic. Combination resulted in a significant higher
number of early-apoptotic IGROV1 cells compared to
177Lu-DOTA-chCE7 alone (40 ± 4%; p < 0.0125) indicat-
ing that enhanced levels of induced DSBs (Fig. 3 and 4e)
resulted in significantly increased early-apoptosis imme-
diately after combined treatment, but not significantly
compared to MK1775 monotreatment (p > 0.0125). The
amount of late-apoptotic or necrotic cells did not vary
significantly (Table 2).
Immunohistology reveals significant higher levels of DNA-
DSBs in SKOV3ip xenografts administered with MK1775
as a single agent or in combination with 177Lu-DOTA-
chCE7
Two in vivo experiments were performed in order to as-
sess whether the promising results from the in vitro
work could be confirmed. First we analysed the immu-
nohistochemical expression of the γH2A.X antigen in
SKOV3ip xenografts after administration of MK1775
and 177Lu-DOTA-chCE7. A generalized increase in
γH2A.X expression (brown staining) was evident in the
xenografts exposed to MK1775 (used alone or in com-
bination; Fig. 5c and d), when compared to those un-
treated (Fig. 5a) or exposed to 177Lu-DOTA-chCE7
monotreatment (Fig. 5b). A 10-fold higher magnification
clearly demonstrates the difference in γH2A.X expres-
sion levels in controls (Fig. 5e) and combination therapy
treated tumours (Fig. 5f ). Observations were confirmed
by γH2A.X foci counts (Fig. 5g), which were conducted
following the criteria applied to in vitro immunofluores-
cence experiments. Control tumours and those received
177Lu-DOTA-chCE7 showed identical levels of γH2A.X
foci (177Lu-DOTA-chCE7: 20 ± 7%; control: 21 ± 9%). In
contrast, tumours treated with MK1775 or the combin-
ation therapy demonstrated similar, but higher amounts
of γH2A.X foci (MK1775: 41 ± 2%; p < 0.0125; combin-
ation: 42 ± 8%, p > 0.0125) compared to the RIT or
control.
RIT with177Lu-DOTA-chCE7 and MK1775 reduces tumour
growth in an IGROV-1 xenograft model
In a second in vivo study we analysed the tumour
growth inhibition effect of a 177Lu-DOTA-chCE7 RIT in
combination with MK1775. We have previously shown
that the use of lutetium-177 labelled anti-L1CAM anti-
body chCE7 for RIT of ovarian cancer is suitable [17]
and a combination with paclitaxel improved the out-
come [19]. For this study we used an advanced tumour
stage (mean tumour volume: 362 ± 150 mm3, maximal
tumour size ≤700 mm3) to see whether RIT in combin-
ation with MK 1775 is able to curb a late stage of the
disease. We observed a fast increase in tumour mass in
the control mice and in the mice treated with MK1775
illustrated an unrestrained tumour growth (Fig. 6). In
contrast, anti-L1CAM RIT alone or in combination with
MK1775 markedly reduced tumour growth in compari-
son to the control group (PBS) and the MK1775 treated
mice. The unspecific 177Lu-labelled control mAb in
combination with MK1775 influenced the tumour
growth to a moderate extent (Fig. 6). During therapy no
signs of distress or lost of body weight of the mice were
observed. Statistical calculations were omitted because
of the modest sample size.
Discussion
Initially, we investigated five clinically relevant PKIs
(MK1775, alisertib, MK2206, temsirolimus and saracati-
nib; clinical phase I-II) towards their cytotoxicity against
the two OC cell lines IGROV1 (p53wt) and SKOV3ip
(p53del). PKIs MK1775 and alisertib demonstrated the
highest toxicity against both cell lines and were further ex-
amined towards their ability to increase the efficacy of
177Lu-labelled mAb chCE7. Both PKIs led to a decreased
IC60-value of the RIC demonstrating their ability to
sensitize the p53wt celI line IGROV1 towards the
177Lu-labelled mAb. However, MK1775 was more efficient
in combination with 177Lu-DOTA-chCE7 compared to
the PKI alisertib. We therefore continued to investigate
the influence of different treatment sequences of
Table 2 Percentage of early- and late-apoptotic/necrotic IGROV1 cells after treatment with MK1775 and 177Lu-DOTA-chCE7
IGROV1 Untreated control MK1775 [300 nM] 177Lu-DOTA-chCE7 [5.0 MBq/ml] Combined treatment
Early-apoptosis 4% ± 1 8% ± 2 29% ± 10 40% ± 4
Late-apoptosis/necrosis 9% ± 2 10% ± 2 13% ± 2 12% ± 1
The data were generated from three independent flow cytometry experiments
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combined MK1775 and 177Lu-DOTA-chCE7 applications
on IGROV1 cells. The influence of the p53 status for
sensitization to radiation by MK1775 is contradictory in
the literature and is discussed in detail by Geenen and
Schellens [40].
MK1775-based sensitization of tumour cells towards
DNA-damaging agents and EBRT, by abrogating the G2
cell cycle checkpoint and inhibiting DNA-repair, has
been previously demonstrated in various cancer cell lines
[26, 27, 41–43]. In our studies, the simultaneous applica-
tion of 177Lu-DOTA-chCE7 and PKI MK1775, as well as
a RIC pre-treatment resulted in 2–3-fold lower IC50-va-
lues compared to 177Lu-DOTA-chCE7 alone against
IGROV1 cells. These results demonstrate the ability of
MK1775 to sensitize IGROV1 cells towards RICs. Thus,
our observations are in line with previous findings for
combinations with EBRT [27, 43]. However, the addition
of MK1775 prior the RIC showed no increased efficacy
Fig. 5 yH2A.X expression in SKOV3ip xenografts. Mice either received (a) PBS (b) 2 MBq 177Lu-DOTA-chCE7, (c) 50 mg/kg MK1775 p.o. for 3
consecutive days, or (d) combined treatment of 177Lu-DOTA-chCE7 with 50 mg/kg MK1775 p.o. for 3 consecutive days started 48 h post RIT. 10-
fold higher magnifications are shown for (e) control tumours and (f) combination therapy tumour samples. γH2A.X foci were counted and cells
grouped depending on 1) no observed, 2) diffuse, 3)≤ 5, 4) ≥ 6, or 5) non-distinguishable γH2A.X foci (intensively positive). (g) summarizes counts
of yH2A.X expressing cells in percent of total cell count
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compared to 177Lu-DOTA-chCE7, pointing out the im-
portance of treatment sequence investigations. Previ-
ously it has been shown that upon radiation-induced
DNA damages the phosphorylation of CDC2 is main-
tained for 12 h in order to arrest the cell cycle in the G/
2 M phase for DNA-repair [44]. We observed an in-
creased radiosensitivity of IGROV1 cells when MK1775
was applied post or simultaneously with 177Lu-DO-
TA-chCE7, suggesting that both, the abolishment of
already existing G2/M arrest and the inability to activate
and maintain the G2/M arrest are forcing cells with
damaged DNA into cell death.
We examined the induction of DNA-DSBs and apop-
tosis by mono- and combined treatments. Levels of his-
tone H2A.X phosphorylation at Ser-139 (yH2A.X) was
measured since it well correlates with the amount of
existing DNA-DSBs [45]. Western blot analysis revealed
slightly increased amounts of yH2A.X in 177Lu-DO-
TA-chCE7 treated IGROV1 cells compared to controls
40 h post RIC application. For EBRT it has been shown
that radiation-induced DNA-damages could be repaired
within 12-24 h post treatment [44]. However, since mAb
chCE7 internalizes and deposits the therapeutic radio-
nuclide 177Lu within the tumour cell, radiation exposure
continues leading to increased amounts of present DBSs
even after 40 h post 177Lu-DOTA-chCE7 removal.
Wee1-inhibiting MK1775 was shown to have multiple
effects on tumour cells: First, replicative stress based on
inactivated CDC2, enhanced initiation of DNA-replication
and thus, shortage of nucleotides and lowered replication
fork speed was observed [46]. Second, it was demon-
strated that Wee1 also negatively regulates the
Mus81-Eme1 endonuclease complex [47]. In turn, Wee1
inhibition most likely leads to increased Mus81-Eme1
endonuclease activity resulting in higher amounts of
DNA-DSBs during DNA-replication. In line with these
studies we showed enhanced levels of yH2A.X in IGROV1
cells after MK1775 applications compared to controls or
177Lu-DOTA-chCE7. Furthermore, the combined admin-
istration of MK1775 and 177Lu-DOTA-chCE7 showed
higher levels of yH2A.X in IGROV1 cells compared to
MK1775 or 177Lu-labelled mAb alone. This indicates that
Wee1 inhibition prevented the repair of irradiation in-
duced DNA-DSBs. Additional evaluation of induced
yH2A.X foci via immunofluorescence confirmed previ-
ously obtained results showing significantly increased
amounts of yH2A.X positive cells after combined applica-
tion of MK1775 and 177Lu-DOTA-chCE7. The synergistic
effect of MK1775 in combination with 177Lu-DO-
TA-chCE7 is therefore likely attributed to replicative stress
and increased DNA damage induced by Wee1 inhibition.
Subsequent analysis of apoptosis/necrosis was per-
formed to further examine if induced DNA-DSBs results
in increased cell death. It has been shown in an osteosar-
coma model that caspase activation upon combination
of MK1775 and EBRT was significantly higher compared
to only irradiated cells [43]. In our investigations, annex-
inV/PI analysis of IGROV1 cells revealed a significantly
increased number of early-apoptotic cells for the com-
bination of MK1775 with 177Lu-DOTA-chCE7 compared
to 177Lu-DOTA-chCE7 treatment alone. This observa-
tion matches the previous findings from PosthumaDe-
Boer et al. [43]. Furthermore, our results demonstrate a
correlation between the number of induced yH2A.X foci
and increased early-apoptosis.
SKOV3ip showed a 3-fold higher IC50-value compared
to IGROV1 cells for 177Lu-DOTA-chCE7. This observa-
tion supports the results of previous experiments with
EBRT showing the highest radioresistance for SKOV3
cells compared to other OC cell lines [48]. Reasons for
radioresistance have been recently discussed by Cojoc et
al. [49]. Cancer cells exhibit multiple mechanisms to
Fig. 6 Therapeutic efficacy of anti-L1CAM lutetium-177 RIT in combination with MK1775 in nude mice bearing subcutaneous IGROV1 tumours.
Tumour-bearing nude mice (n = 4–6) were treated with 6 MBq (50% MTA) 177Lu-DOTA-chCE7, 6 MBq 177Lu-DOTA isotype control mAb,
combination of both radiolabelled antibodies with MK1775 (given on three consecutive days, starting 48 h after RIT), only MK1775 and only PBS.
Tumour growth curves were stopped when the first tumour in a treatment group reached 1500 mm3. The dashed line represents a 2.5 increase
in mean relative tumour volumes (± SD)
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avoid DNA-damage upon radiation including (i) the
regulation of the cell cycles status, (ii) an improved
DNA-repair machinery and (iii) enhanced DNA protec-
tion against reactive oxygen species (ROS) [49]. The oc-
currence of these mechanisms certainly varies between
cell lines and is most likely more distinct in SKOV3ip
than in IGROV1 cells.
Immunohistology of SKOV3ip xenograft samples con-
firmed in vitro results showing high sensitivity against
MK1775 and high radioresistance. The treatment with
MK1775 for 4 days was enough, to induce elevated levels
of yH2A.X in comparison to control and the treatment
group with 2 MBq 177Lu-DOTA-chCE7. The combin-
ation therapy did not further increase the numbers of
positive cells for yH2A.X. This suggests that MK1775
executes its toxicity in vivo, but additional application of
2 MBq 177Lu-DOTA-chCE7 did not produce further
DNA-DSBs.
Increased therapeutic efficacy of EBRT in combination
with MK1775 has been previously shown by Sarca et al.
[50] in a glioblastoma model. Here we demonstrated that
a combination of lutetium-177 RIT in combination with
MK1775 in a late stage ovarian cancer model (IGROV1
xenograft) inhibited the tumour growth to a greater extent
than the controls. The difference between RIT alone and
the combination therapy was small and probably due to
the modest group size. The influence of the lutetium-177
labelled unspecific antibody in combination with MK1775
on the tumour growth was moderate which is most
likely due to a nonspecific accumulation of the mAb at
the tumour site. Inflammations are sites where unspe-
cific accumulation of radiolabelled antibodies occur
[51]. The mice carried relative big tumours at therapy
start and inflammation is often associated with
tumour progression [52].
Conclusion
To our knowledge this is the first time that RIT was
combined with MK1775 and the results were reported.
MK1775 radiosensitizes ovarian cancer cells and a com-
bination with 177Lu-labelled anti-tumour antibody in-
creased the efficacy of the treatments. Our results
strongly support a further development of a combination
of MK1775 with RIT.
Additional file
Additional file 1: Figure S1. Flow cytometry analysis revealed that over
98% of IGROV1 and SKOV3ip cells expressed L1CAM on the cell surface.
Figure S2. MK1775 showed most promising radiosensitizing effect in
IGROV1 human OC cells. Table S1. Combination index (CI). Detailed
information on the CI was shown. Data from Fig. 2 were used for the
calculations. Table S2. Quantification of γH2A.X foci in IGROV1 cells
treated with either 100 nM MK1775 (48 h), 2.5 MBq 177Lu-DOTA-chCE7
(4 h), or both. Detailed information about the γH2A.X foci (≤ 5/cell, ≥ 6/
cell, Intensively positive cells) after treatments is shown in percent of
total cell count. Figure S3. Apoptosis/necrosis analysis of IGROV1.
AnnexinV-FITC/PI double staining was used to distinguish between
early- and late-apoptosis/necrosis. Enhanced levels of induced DSBs
resulted in significantly increased early-apoptosis immediately after
combined treatment. (DOCX 410 kb)
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